This is a StreetInsider.com Premium Only Page

Epizyme (EPZM) – StreetInsider.com Reports

Jun 27, 2022 04:49 PM Cowen Downgrades Epizyme (EPZM) to Market Perform

Jun 27, 2022 09:30 AM Pre-Open Stock Movers 06/27: Chewy Gains on Upgrade; Spirit Airlines Falls on Deal Update

Jun 27, 2022 08:08 AM Wedbush Downgrades Epizyme (EPZM) to Neutral

Jun 27, 2022 05:55 AM Epizyme (EPZM) Acquired by Ipsen for for $1.45/sh + CVRs

Jun 2, 2022 07:05 AM Epizyme (EPZM) Reports Updated SYMPHONY-1 Study Data

May 12, 2022 06:20 AM Epizyme (EPZM) PT Lowered to $8 at H.C. Wainwright

May 10, 2022 03:21 PM Epizyme (EPZM) PT Lowered to $7 at Wedbush

May 10, 2022 07:19 AM Epizyme (EPZM) Misses Q1 EPS by 3c

Apr 6, 2022 05:23 PM Epizyme (EPZM) Chief Medical and Development Officer Resigns

Mar 1, 2022 07:50 AM Epizyme (EPZM) PT Lowered to $385 at Stifel

Mar 1, 2022 07:05 AM Epizyme (EPZM) Misses Q4 EPS by 4c

Jan 27, 2022 09:17 AM Pre-Open Stock Movers 01/27: (GLPG) (NOW) (XM) Higher; (EPZM) (LC) (ZYME) Lower (more...)

Jan 27, 2022 05:54 AM Epizyme (EPZM) Prices 56.7M Share Offering at $1.50/sh

Jan 26, 2022 05:58 PM After-Hours Stock Movers 01/26: (NOW) (XM) (NFLX) Higher; (EPZM) (LC) (ZYME) Lower (more...)

Jan 26, 2022 04:02 PM Epizyme (EPZM) Announces Proposed Stock Offering, Size not Disclosed

Jan 19, 2022 11:48 AM Epizyme (EPZM) granted FDA Orphan Drug Designation for multiple myeloma treatment

Dec 13, 2021 05:24 AM Epizyme (EPZM) Reports Preclinical Data and Phase 1/1b Trial Design on EZM0414

Dec 13, 2021 05:09 AM Epizyme (EPZM) Reports Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study

Nov 18, 2021 06:36 AM Epizyme (EPZM) Announces Updates to Its Board of Directors

Nov 9, 2021 04:37 PM Epizyme (EPZM) PT Lowered to $12 at Cowen, Following Earnings

Nov 9, 2021 06:37 AM Epizyme (EPZM) Misses Q3 EPS by 16c

Nov 4, 2021 06:30 AM Epizyme (EPZM) Granted FDA Fast Track Designation and Initiates Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414

Oct 29, 2021 06:54 AM Epizyme (EPZM) Announces Retirement of Chief Strategy and Business Officer

Sep 21, 2021 07:15 AM Epizyme (EPZM) Files For 5.65M Share Secondary Offering

Aug 10, 2021 03:34 AM Morgan Stanley Downgrades Epizyme (EPZM) to Underweight

Aug 9, 2021 03:51 PM Morgan Stanley Downgrades Epizyme (EPZM) to Equalweight, Following Earnings, CEO Succession

Aug 9, 2021 09:34 AM Pre-Open Stock Movers 08/09: (GNOG) (SIC) (BNTX) Higher; (ATER) (BIVI) (AXSM) Lower (more...)

Aug 9, 2021 07:35 AM Epizyme (EPZM) Announces CEO Succession

Aug 9, 2021 07:34 AM Epizyme (EPZM) Misses Q2 EPS by 1c

Jun 16, 2021 06:35 AM Epizyme (EPZM) Launches EZH2Now Testing Program with Quest Diagnostics for R/R Follicular Lymphoma Patients

May 7, 2021 07:17 AM SVB Leerink Upgrades Epizyme (EPZM) to Outperform

May 7, 2021 04:18 AM Epizyme (EPZM) PT Lowered to $21 at Citi

May 6, 2021 04:14 PM Epizyme (EPZM) PT Lowered to $10 at Morgan Stanley

May 6, 2021 03:20 PM Epizyme (EPZM) PT Lowered to $26 at Wedbush, Following Earnings

Apr 23, 2021 05:31 AM Cowen Assumes Epizyme (EPZM) at Outperform

Mar 30, 2021 04:08 PM Credit Suisse Starts Epizyme (EPZM) at Outperform

Mar 2, 2021 12:00 PM Epizyme (EPZM) Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Feb 25, 2021 02:57 AM Morgan Stanley Downgrades Epizyme (EPZM) to Equalweight

Feb 23, 2021 06:37 AM Epizyme (EPZM) Misses Q4 EPS by 7c

Jan 20, 2021 09:56 AM Epizyme (EPZM) on Watch on Chatter

Dec 21, 2020 07:36 AM UPDATE: Jefferies Downgrades Epizyme (EPZM) to Hold

Nov 9, 2020 04:45 AM Epizyme (EPZM) PT Lowered to $18 at Barclays

Nov 6, 2020 02:31 PM Epizyme (EPZM) PT Lowered to $12 at SVB Leerink, Following Earnings

Nov 6, 2020 06:43 AM Epizyme (EPZM) Tops Q3 EPS by 5c, Revenues Miss

Nov 6, 2020 06:14 AM Epizyme (EPZM) Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives

Oct 30, 2020 06:55 AM Epizyme (EPZM) PT Lowered to $27 at Wedbush

Oct 7, 2020 06:31 AM Epizyme (EPZM) Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

Oct 5, 2020 09:42 AM Epizyme (EPZM) Highlighted on Sector Deal

Aug 5, 2020 08:22 AM Epizyme (EPZM) PT Lowered to $29 at Morgan Stanley

Aug 4, 2020 11:38 AM Epizyme (EPZM) PT Lowered to $28 at Jefferies, Following Earnings